Predicting Early Weight Loss in Radiotherapy
Dirk De Ruysscher, MD, PhDStudy shows emerging techniques may improve prognostic and predictive models in identifying patients at risk for early weight loss. Read more
In Brief for February 9, 2022
John AustinTTLC goes virtual. Positive results reported for pembrolizumab. GO2 Foundation names Chief of Healthcare Delivery. Read more
When facing a grave illness, especially for the first time, many people are worried, frightened, and overwhelmed. They may have difficulty focusing their attention on daily tasks and experience skewed […] Read more
Multifaceted Initiative Launches Aimed at Reducing Lung Cancer Deaths 25% by 2030
Raymond U. Osarogiagbon, MBBS, FACPThe Baptist Cancer Center in Memphis, Tennessee, has launched a new initiative that comprises seven components that will address prevention, diagnosis, and treatment of lung cancer through smoking cessation, low-dose […] Read more
Data from multiple groups1,2 have shown the significant impact of COVID-19 infection among patients with malignancies, leading to high overall morbidity and mortality; this includes our own institution,3 which saw […] Read more
Pembrolizumab Plus Platinum-Doublet Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Unresectable, Locally Advanced Stage III NSCLC: The KEYNOTE-799 Trial in Perspective
Noemí Reguart+more
Approximately one-third of patients with NSCLC are diagnosed with unresectable, locally advanced (LA) stage III disease.1 Historically, the standard of care for these patients has been concurrent platinum-based chemotherapy with […] Read more
Intratumoral Dendritic Cells in Treatment of Lung Cancer
Joachim Aerts, MD, PhDIn the past decade, targeting of the PD-1/PD-L1 checkpoint, with or without CTLA-4 targeting, has revolutionized cancer treatment. However, a significant proportion of patients with lung cancer still do not […] Read more
Comprehensive Analysis of Proteomics Identifies New, Druggable Drivers of NSCLC—and New Avenue for Continued Research
Beth Fand IncollingoDespite the past decade’s accomplishments in identifying the genetic drivers of NSCLC, the complexity of these cancers continues to create barriers to effective targeted treatment. Finding strategies capable of overcoming […] Read more
The eNRGy1 Global Multicenter Registry: NRG1 Fusions as a Hidden Target in Lung Cancer
Stephen Liu+more
Gene fusions involving ALK, ROS1, RET, and NTRK are now established targets in NSCLC, for which highly effective and well-tolerated kinase inhibitors are the preferred initial therapy. A growing body […] Read more
Not all published papers are on equal footing. Read more